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Summary
Presentation of exogenous protein antigens to T lymphocytes is based on the intersection of
two complex pathways: (a) synthesis, assembly, and transport of major histocompatibility com-
plex (MHC) class II-invariant chain complexes from the endoplasmic reticulum to a special-
ized endosomal compartment, and (b) endocytosis, denaturation, and proteolysis of antigens
followed by loading of antigenic peptides onto newly synthesized MHC class 11 molecules. It is
believed that expression of MHC class II heterodimers, invariant chain and human leukocyte
antigen-DM is both necessary and sufficient to reconstitute a functional MHC class II loading
compartment in antigen-presenting cells. Expression ofeach ofthese essential molecules is un-
der the control of the MHC class II transactivator CIITA. Unexpectedly, however, whereas
interferon y stimulation does confer effective antigen-processing function to nonprofessional
antigen presenting cells, such as melanoma cells, expression ofthe CIITA transactivator alone is
not sufficient. Activation of antigen-specific T cells thus requires additional CIITA-indepen-
dent factor(s), and such factor(s) can be induced by interferon y .
T
he MHC class II transactivator CIITA has been de-
scribed as a transcription factor necessary for the regu-
lation of both constitutive (1) and IFN-y-induced (2) ex-
pression of MHC class II genes. CIITA transfection into
various human cell lines was found to be able to induce
surface expression of MHC class 11 molecules to levels sim-
ilar to those induced upon IFN-y treatment (2) .
This essential role of CIITA suggested that MHC class
II-negative, nonprofessional APC could be converted by
CIITA transfection into MHC class 11-positive cells able to
activate antigen-specific, class II-restricted T cells. The po-
tential interest ofthis approach in the field ofimmunother-
apy prompted us to address this possibility. We present here
the functional analysis of CIITA-transfected human mela-
noma cells acting as APC for HLA-DR-restricted CD4+ T
lymphocytes. CIITA transfection is able to confer antigen
presentation function when cells are provided with peptide
antigen, but, unexpectedly, the same transfectants remain
deficient in processing of protein antigens. The analysis of
the structural and functional characteristics of CIITA trans-
fectants identified an antigen-processing defect that exhibits
a novel phenotype. Correction of this antigen-processing
defect by IFN-y treatment indicates that factor(s) other
than MHC class II, invariant chain (Ii),' and DM, which
'Abbreviations used in this paper: HA, hemagglutinin; Ii, invariant chain;
NRS, normal rabbit serum; OVN, overnight.
are all induced by CIITA expression are necessary for opti-
mal processing and presentation by nonprofessional APC
such as melanoma cells.
Materials and Methods
Cells and Culture Conditions.
￿
Human melanoma cellsMe67 and
Me208were grown in RPMI-1640 medium complemented with
glutamine, 10% heat-inactivated (56°C) FCS, and antibiotics.
Cells were incubated at 37°C in 5% CO, and maintained in a
logarithmic growth phase with a viability >98% at all steps. For
MHC class II induction, cells were incubated with humanrIFN-y
(specific activity = 1.4 X 107 U/mg; gift from Biogen Inc., Cam-
bridge, MA) at 500 U/ml for 24 or 48 h, as indicated in figure
legends.
Transfections. Melanoma cell lines were transfected by cal-
cium phosphate precipitation followed 4 h later by a glycerol
shock with either the expression vector EBO-Sfi alone or a full-
length CIITA cDNA cloned into EBO-Sfi under control of
SV40 promoter (1, 2). Stable transfectants were generated by se-
lection with hygromycin B (Calbiochem Corp ., La Jolla, CA) and
maintained in culture with hygromycin throughout the study, in-
cluding during IFN-y induction.
Surface MHC Class 11 Expression.
￿
Duplicate samples of2 X 105
cells were washed, preadsorbed with 10% normal rabbit serum
(NRS), incubated with NRS or relevant antibodies followed by
fluorescein-conjugated rabbit anti-mouse IgG (Serotec Ltd.,
Oxford, UK), washed, and analyzed by flow cytometry on a
FACScana analyzer (Becton Dickinson & Co., Mountain View,
CA). 10,000 cells were analyzed for each determination.
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￿
Polymorphic HLA-DR mAB2.06 (3), mAb GSP-
142 .2 (Genetic System Corp ., Seattle, WA), GSP87.1 (id.), and
mAbs M2, 16.23, A2, and KS.6 (4) were used at saturating con-
centrations for indirect immunofluorescence and immunoprecip-
itation (mAb D1 .12; reference 5) studies.
SDS Stability ofMHC Class II Dimers.
￿
lmmunopreeipitation of
MHC class 11 molecules was done as described (5) . Briefly, 10 X
10 6 cells per point were labeled for 8 h at 37 °C with 500 N.Ci of
[35S]methionine (Amersham Corp ., Arlington Heights, IL) in . 5
ml ofRPMI medium lacking methionine and containing 2% dia-
lyzed FCS . Cells were then washed extensively in cold PBS be-
fore lysis fo 20 min at 4°C in 1 ml ofTris-buffered saline contain-
ing 1% NP-40 detergent (5) . Insoluble material was removed by
centrifugation at 100,000g for 30 min . Cell extracts were incu-
bated three times for 2 h at 4°C with protein A-Sepharose 4 Fast
Flow beads (Pharmacia, Uppsala, Sweden) under rotation to re-
move nonspecifically bound material . Class II molecules were
then immunoprecipitated by using mAb D1 .12, previously
bound to protein A-Sepharose beads, for4 h at 4°C. Cell extracts
were then washed three times in Tris-buffered saline with 0.5%
NP-40 . Samples were resuspended in 2% SDS buffer containing
10% glycerol and split in two portions, one of which was boiled
for 5 min and one of which was left at room temperature for 30
min . Samples were separated on 10.5% polyacrylamide gels be-
fore autoradiography .
T Cell Lines .
￿
T-19 is aT cell line specific for the p2 peptide
oftetanus toxin (tt830-843), which is restricted by the DRB1*11
and DRB1*08 alleles (6), whereas T-87 recognizes the p4 pep-
tide (tt 1273-1284) presented by DRB3*0101 (data not shown),
T cell lines were generated as described (6) . RPMI-1640 supple-
mented with 15% human AB+ serum from male volunteer do-
nors was used as culture medium . T cell lines were restimulated
for expansion with autologous irradiated PBMC, preincubated
with p2 or p4 peptides, in IL-2-supplemented culture medium .
Expanded T cell lines were frozen in culture medium-DMSO
10% and stored in liquid nitrogen .
Antigen Presentation to T Cells .
￿
Melanoma cells (106) were in-
cubated for 16 h with various concentrations of tetanus fragments
Tet3 (tt 744-1315, reference 7), C (Fr-C, tt 865-1315), B (Fr-B,
tt 2-864), or medium alone, fixed with 0.2% paraformaldehyde,
washed, and used as APC (3 X 104 cells/well) in coculture with
tetanus-specific T cell lines (2 X 10 4 cells/well) as described (6) .
Alternatively, melanoma cells were fixed and preincubated with
various concentrations of tetanus p4 or p2 synthetic peptides be-
fore washing and coculture with T cells . The proliferative re-
sponse oftetanus-specific T cell lines was measured after 48 h by
[3H]thymidine incorporation as described (6) .
Peptide Binding,
￿
Binding assays were performed as described
(8) . Briefly, 3 X-105 melanoma cells, either CIITA transfected or
IFN-'Y treated, were incubated at 37 °C for 4 h with various con-
centrations of a biotinylated peptide (HA 307-319) of influenza
hemagglutinin (HA) (9) or medium alone . In competition exper-
iments, cells were first incubated with a large excess of nonbio-
tinylated HA peptide . After washing, cells were incubated with
FITC-streptavidin 4.22 lt,g/ml, Calbiochem Corp .) at 4°C for 30
min . Stained cells were washed again and analyzed by flow cy-
tometry as described above .
Results
Antigen Presentation Function of CIITA Transfectants .
CIITA-transfected or IFN-y-treated Me67 and Me208
melanoma cells were first compared by indirect immuno-
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fluorescence analysis for their level of surface HLA-DR
molecules . Similar staining intensity by HLA-DR-specific
mAbs were observed under both conditions in both cell
lines (Fig . 1 A), confirming our previous findings on the
role of CIITA on MHC class II induction (2) . Profiles of
cells transfected with theEBO-Sfivector alonewere super-
posable with those of untransfected, noninduced cells (data
not shown) . Furthermore, the rate of synthesis of HLA-
DR molecules is identical in CIITA-transfected or IFN-y-
treated Me67 cells (see below) .
We next assessed the functional capacity of CIITA-trans-
fected or IFN-y-treated MHC class II-positive cells to
present tetanus toxin antigen to tetanus-specific T cell clones .
Figure 1 .
￿
Antigen presentation by CIITA-transfected or IFN-,Y-treated
melanomas . (A) Surface expression of HLA-DR on Me67 and Me208
cells transfected with CIITA or incubated with 500 U/ml of IFN-y for
48 h . Cells were analyzed by flow cytofluorimetry for the expression of
HLA-DR (mAb 2.06) . Blank profiles on the left represent cells incubated
withNRS and the second reagent alone . (B) Specific recognition by T-19
T cells o£ exogenous tetanus toxin presented by Me208 cells transfected
with CIITA or incubated with 500 U/ml ofIFN-y for 24 h before OVN
incubation with 10 jig/nil of tetanus fragment Tet3 (tt 744-1315, ref5)
or medium alone. (C) Specific recognition of exogenous tetanus toxin
presented by Me67 cells . IFN-y-treated (--E- ) or CIITA transfected
(-a-) cells were incubated OVN with various concentrations oftetanus
toxin fragment C (Fr-C, tt 865-1315) before fixation and coculture with
T-87 cells. (D) Presentation of exogenous synthetic peptide by CIITA-
transfected Me67 cells . CIITA-transfected (--a-) or control Me67 cells
(~-) were fixed and preincubated OVN with various concentrations of
p4 synthetic peptide before washing and coculture with T-87 cells .Me208 cells that were either CIITA transfected or preincu-
bated with 500 U/ml of IFN-y for 24 h were incubated
overnight (OVN) with 10 lLg/ml of tetanus fragment Ter
3, fixed, and used as APC in coculture with the tetanus-
specific T-19 T cell line (Fig . 1 B) . This T cell line, specific
for the p2 peptide oftetanus toxin (tt 830-843), is restricted
by the DRB1*11 and DRB1*08 alleles (6) . IFN-y induc-
tion ofMHC class II molecules readily conferred to Me208
melanoma cells expressing DRB 1* 1101 /04 alleles (oligo-
typing, data not shown) the capacity to activate T-19 lym-
phocytes . In contrast, CIITA-transfectedMe208 expressing
similar amounts ofMHC class II molecules (Fig . 1 A) were
unable to activate the T-19 cell line . This dramatic differ-
ence in antigen presentation capacity between IFN-y-
induced and CIITA-transfected cells was also observed un-
der similar conditions with a different melanoma cell line
(Me67, DRB1*1301/04, DRB3*0101) presenting a different
epitope (peptide p4, tt 1273-1284) to a T cell line restricted
by a different HLA molecule, the DR133*0101-restricted
T-87 cell line (Fig . 1 C) .
In contrast, when the same CIITA-transfected mela-
noma cells unable to process and present native tetanus
protein antigen to T cells were incubated with various con-
centrations of synthetic tetanus peptides, a dose-dependent
peptide-specific DR-restricted activation ofT cell lines was
induced (Fig . 1 D) . Thus, CIITA trans£ection of class II-
negative melanoma cells induces a normal expression of
surface MHC class II molecules that are able to bind and
present exogenous peptides to specific, DR-restricted T
cells . Curiously, however, it creates an antigen-processing-
deficient phenotype .
Stability ofMHC Class II Dimers in CIITA Transfectants .
The description ofHLA-DM mutant B cell lines character-
ized by impaired processing of exogenous native antigens,
loss of MHC class II SDS stability at room temperature,
and expression of distinct MHC class II conformational
epitopes (10-14) prompted us to first address the possibility
of a similar phenotype in CIITA transfectants . To analyze
the SDS stability of their class II dimers, CIITA-transfected
or IFN--Y-treated Me67 cells were labeled with [35S]me-
thionine before immunoprecipitation of MHC class It
molecules with mAb D1.12 . Samples resuspended in 2%
SDS buffer were split into two portions, one of which was
boiled for 5 min and one ofwhich was left at room tem-
perature for 30 min before electrophoresis (Fig . 2 A) . Im-
munoprecipitation of newly synthesized HLA-DR mole-
cules in either CIITA-transfected or IFN-y-treated Me67
cells demonstrated (a) a similar rate ofHLA-DR biosynthe-
sis and associated Ii, and (b) a similar pattern ofSDS stability
of class II dimers . Thus, in contrast to what was observed in
HLA-DM-mutant B cell lines, the antigen-processing de-
fect ofCIITA transfectants does not prevent the formation
of SDS-stable class II dimers .
The induction ofboth HLA-DM and Ii chains by CIITA
transfection has been documented (15, 16) in all cell types
examined, and specifically confirmed in the melanoma cell
lines used in this study . In the CIITA-transfected or IFN-
y-treated Me67 melanoma cells, the steady-state mRNA
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Figure 2 .
￿
Conformation ofMHC class II dimers in CIITA-transfected
or IFN-y-treated melanoma cells . (A) Formation of SDS-stable MHC
class II dimers in Me67 cells treated (+) or not (-) with IFN-y and in
Me67-CIITA cells . Class II molecules immunoprecipitated in SDS sam-
ple buffer were either boiled (100 °C) or left at room temperature before
separation on SDS-PAGE and autoradiography . a(3, DR heterodimers;
a, DRa monomers; R, DRR monomers . (B) Different conformation of
MHC class II molecules at the surface of melanoma cells . CIITA-trans-
fected (blank) or IFN-y-treated (black) Me67 cells (1-4) and Me108 cells
(5-8) were analyzed by flow cytofluorometry for the expression of HLA-
DR (1-6) or-DQ (7 and 8) with a panel ofMHC class II-specific mAbs
(18) . Blank profiles on the left (dotted line) represent melanoma cells incu-
bated with NRS and the second reagent alone .
ratio of HLA-DR/Ii/DM is strictly conserved quantita-
tively (RNase protection analysis, data not shown) . In
terms of intracellular localization of HLA-DR molecules,
no differences were observed by confocal microscopy be-
tween CIITA-transfected or IFN-y-treated Me67 cells (data
not shown) .
Surface Conformation ofMHC Class II Molecules .
￿
The al-
tered conformation of surface MHC class II molecules has
been described as another phenotypic feature of antigen-
processing-deficient mutants (17-19) . Surface MHC class
II conformation was therefore studied in CIITA-transfected
or IFN-y-treated Me67 cells expressing strictly similar
amounts ofMHC class II molecules when stained withO
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￿
Peptide binding by surface MHC class 11 molecules. Me67
cells that were either IFN-y treated (1-4) or CIITA transfected (5-8)
were analyzed by flow cytofluorometry for surface expression of HLA-
DR (nuSb 2.06, 1 and 5) or incubated with the indicated concentrations
of biotinylated HA307-319 peptide before staining with FITC-streptavi-
din and analysis by flow cytofluorometry. Profiles on the left indicate cells
incubated with the second reagent alone. In competition experiments (4
and 8), cells were firstincubated with an excess ofnonbiotinylated HA307-
319 (250 p,M) before addition of biotinylated peptide.
polymorphic HLA-DR r Ab (Fig. 1 A and Fig. 2 B, 1) .
Out of a large panel of anti-DR, -DP, and -DQ mAbs se-
lected for their relative specificity for a given HLA haplo-
type, a few antibodies consistently distinguished HLA-DR
or HLA-DQ molecules expressed on the same melanoma
cell line that was either CIITA transfected or INF-y treated
(Fig. 2 B, 2-8). Certain mAbs such as KS6 (Fig. 2 B, 8)
recognized INF-y-treated cells 10 times better than CIITA
transfectants. Other mAbs, such as M2 and 16.23, clearly
recognized a determinant of MHC class 11 molecules at the
surface of HLA-DR13 (Me67)+ or HLA-DR11 (Me208)'
CIITA, but not IFN-y-treated cells (Fig. 2 B, panel 4). Last,
depending on the cell haplotype, mAb GSP87.1 recog-
nized an HLA-DR epitope of CIITA-transfected (Me67)
cells or IFN-y-induced (Me208) cells (Fig. 2 B, 2 and 6) .
No direct correlation was thus found across haplotypes be-
tween expression ofa given epitope and antigen-processing
capacity. However, the distinction between MHC class 11
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molecules induced at the surface of the same cell lines by
CIITA transfection or by IFN-'Y stimulation indicated that
these molecules, present in similar amounts, adopt different
surface conformations. These different conformations could
well reflect the intracellular binding of different sets ofpep-
tides by MHC class II molecules synthesized under both
conditions.
Peptide-binding Capacities of Surface MHC Class II Mole-
cules. The adherent phenotype and relatively stringent
culture requirements ofour melanoma cell lines did not al-
low culture of a number of cells sufficient for direct elution
of MHC class II bound peptides. Nevertheless, to explore
the possibility that different sets ofpeptides could be present
within the groove of surface class 11 dimers in the two con-
ditions, we assessed the capacity of surface class II mole-
cules to bind an exogenously provided synthetic peptide.
CIITA-transfected or IFN-y-induced Me67 cells express-
ing similar levels of surface class 11 molecules (Fig. 3, 1 and
5) were incubated with a biotinylated influenza peptide
(HA 307-312) known to bind to HLA-DR4 (9) before ad-
dition of FITC-streptavidin and analysis by flow cytom-
etry. Surprisingly, the patterns of fluorescence observed
were markedly different. Whereas little binding above au-
tofluorescence was detected for IFN-y-treated cells, which
is consistent with binding by <2% of surface class 11 mole-
cules, Fig. 3 shows a strong, dose-dependent increase of
fluorescence of CIITA transfectants. Competition experi-
ments in which cellswere first incubated with a 10X excess
of nonbiotinylated peptide (Fig. 3, 4 and 8), as well as
blocking experiments with MHC class 11-specific antibod-
ies (data not shown), confirmed the specificity of the fluo-
rescence. Thus, the distinct conformation of MHC class II
molecules expressed at the surface of CIITA-transfected
melanoma cells correlates with an increased peptide-bind-
ing capacity when compared with class 11 dimers ofIFN-y-
treated cells.
Correction of the Antigen-processing Defect of CIITA Trans-
fectants by IFN-y. The fact that IFN-y induction was able
to confer antigen-processing capacity to melanoma cells,
whereas CIITA transfection was not, suggested that the
processing defect of CIITA transfectants could result from
the lack of expression of other IFN-y-inducible essential
factor(s) . The effect of IFN-y on the antigen-processing
ability of CIITA transfectants was therefore studied. Time
course experiments, where CIITA-transfected Me67 cells
were incubated with IFN-y for various periods of time be-
fore incubation with antigen and specific T cell lines, dem-
onstrated IFN-y-dependent restoration of tetanus toxoid
presentation by CIITA transfectants (Fig. 4) . This was not
accompanied by an increase in cell surface HLA-DR ex-
pression (data not shown) . A similar restoration of antigen
presentation was obtained with T cell lines specific for
other tetanus toxin epitopes, restricted by different HLA-DR
alleles, and with the Me208 melanoma cell line (data not
shown) . These results demonstrate that additional factor(s)
induced by IFN-y, but not under the control of CIITA, are
absolutely required to confer antigen-processing capacity to
these nonprofessional APC.Discussion
0-'20 40 60 80
!FN-r induction (h)
Figure 4. IFN--y restoration
ofantigen processingby CIITA-
transfected melanoma cells.
CIITA-transfected Me67 cells
were incubated with 500 U/ml
of IFN--y or medium alone, in
continuous presence of hygro-
mycin, for various periods of
time before OVN incubation
with tetanus toxin Fr-C (20 p,g/
ml) or control antigen (tetanus
toxin Fr-B,tt 2-864, 20 p.g/ml).
The proliferative response ofthe
T-87 cell line to Fr-C (-f-) or
control antigen (-o--) is ex-
pressed as the ratio of stimula-
tion obtained with IFN-.y--treated
versus-untreated cells.
Although expressing similar levels of surface HLA-DR
molecules and synthesizing HLA-DR at similar rates, mela-
noma cells are either capable (IFN-y treatment) or incapa-
ble (CIITA transfection) of presentation of a protein anti-
gen to the relevant T lymphocytes (Fig. 1). In contrast to
these results with protein antigens, CIITA-transfected mel-
anoma cell lines provided with the antigen in the form of
exogenous synthetic peptides readily activate specific T lym-
phocytes. Thus, CIITA transfection of these nonprofessional
APC induces the expression of MHC class If molecules,
confers the capacity of presenting short exogenous peptides
to T cells, but generates a cell phenotype that is defective in
antigen processing and presentation ofnative antigens. This
unusual functional phenotype, which differs from that of
the same cell line after stimulation by IFN-y, suggests that
antigen processing by nonprofessional APC such as mela-
nomas involves yet an additional level of complexity that is
not under the control of the MHC class II transactivator
CIITA.
Studies of HLA-DM-mutant B cell lines have identified
a special phenotype ofAPC characterized by impaired pro-
cessing of some exogenous antigens. Consequently, the
phenotypical features characteristic of HLA-DM mutants
were studied in CIITA-transfected melanoma cells. Immu-
noprecipitation of newly synthesized HLA-DR molecules
in CIITA-transfected and IFN-y-induced cells demon-
strated a similar pattern of SDS stability of class 11 dimers
(Fig. 2 A). We conclude that, contrary to the situation of the
HLA-DM mutants, the antigen-processing defect of CIITA
transfectants does not prevent the formation of SDS-stable
class 11 dimers. The recent demonstration that the forma-
tion of class It SDS-stable dimers requires both Ii and DM
expression (20) also argues for a distinct mechanism respon-
sible for the antigen-processing defects of CIITA transfec-
tants and HLA-DM mutants. In addition, induction of both
HLA-DM and Ii mRNA upon CIITA transfection has
been demonstrated (15, 16) . Since trace amounts of DM
are reported sufficient to stabilize MHC class It molecules
(20), and since the DR/Ii/DM mRNA ratio is identical in
CIITA-transfected and IFN-y-induced cells, these factors
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known to be involved in class II-restricted antigen presen-
tation do not seem to be responsible for the antigen-pro-
cessing defect observed in CIITA transfectants.
MHC class II molecules expressed on certain processing-
defective B cell mutants were shown to exhibit special con-
formational determinants that can be distinguished by cer-
tain mAbs (17-19). This characteristic feature is also present
in antigen-processing-deficient CIITA-transfectants, whose
surface MHC class II dimers exhibit a different conforma-
tion when compared with class II molecules expressed after
IFN--y induction. In the case of HLA-DM-deficient mu-
tant B cell lines, as in CIITA transfectants, the loss of a few
conformational epitopes present on normal cells has been
observed. In our search for mAbs able to distinguish spe-
cific conformational determinants, we also identified mAbs
that recognized MHC class It molecules better or exclu-
sively on antigen-processing-deficient cells (Fig. 2 B) . No
direct correlation was found across HLA haplotypes be-
tween expression o£a given epitope and antigen-processing
capacity. Thus, the change in class 11 conformation that is
associated with the antigen-processing defect of CIITA
transfectants resulted either in enhanced or in reduced rec-
ognition by specific rriAbs. Altogether, these analyses sug-
gest, as was described for murine intestinal cells (21) and
thymic medulla epithelial cells (22), that the conformation
of MHC class 11 molecules at the cell surface reflects the set
of peptides bound within their groove, and thus indirectly
the integrity ofthe antigen-processing pathway. In the case
of nonprofessional APC, such as melanomas the demon-
stration of a distinct structural phenotype appears to corre-
late with antigen-processing capacity better than SDS sta-
bility ofclass II dimers.
The structural differences of surface class II MHC mole-
cules expressed on CIITA transfectants were further sub-
stantiated by the demonstration of a very different capacity
for peptide binding. It was indeed of interest to observe a
stronger binding of an influenza-derived biotinylated pep-
tide to class 11 molecules expressed at the surface ofCIITA-
transfected versus IFN-y-treated melanoma cells (Fig. 3).
Given the similar density of MHC class II molecules ex-
pressed under both conditions, this observation strongly sug-
gests an increased avidity of MHC class 11 dimers of CIITA
transfectants for exogenous peptides. The expression ofsta-
ble MHC class II molecules with distinct conformations
and enhanced binding capacity for peptides suggests that
MHC class II molecules synthesized in CIITA transfectants
do encounter and bind different sets of peptides on theirway
to the cell surface.
The fact that IFN-y can correct the antigen-processing-
defective phenotype of CIITA-transfected melanomas is
important (Fig. 4). It means that in addition to the genes
regulated by CIITA (i.e., MHC class II, HLA-DM, and Ii),
one or more other INF-y-induced genes are required for
antigen processing in some nonprofessional APC. This is in
contrast to what is observed in various mutant B cell lines,
where antigen-processing defects can be restored simply by
expression of MHC class 11, HLA-DM, and Ii (11, 12, 14) .
We thus suggest that these essential additional factors areReferences
Figure 5.
￿
Complexity ofantigen-processing and presentation by MHC
class II molecules in nonprofessional APC.
not constitutively expressed in nonprofessional APC such
as melanomas and that they require cytokine induction. In
these nonprofessional APC, it has been reported that the
presence of HLA-DM and the Ii chain is sufficient to allow
MHC class II molecules to reach the appropriate peptide-
loading compartment (20).
It follows that additional distinct steps should be consid-
ered as candidates for the essential IFN-y-inducible, CIITA-
independent function required for antigen presentation.
Endocytosis does not seem to be involved since kinetic
analysis of fluid-phase endocytosis through flow cytofluo-
rometry (23) indicated an identical level of Lucifer yellow
uptake for both untreated (processing-defective) and IFN-
y-treated (processing-competent) CIITA-transfected cells
(data not shown). Interestingly, there is recent evidence
that IFN-y induces endosomal and lysosomal proteases,
such as cathepsin D and B (24-26), which are involved in
the processing of endocytosed proteins, including tetanus
toxin (27). Thus, the modulation by IFN-y of the activity
or localization of specific proteases could influence the na-
ture of the peptides generated and/or loaded onto MHC
class II molecules.
We propose that effective processing and presentation of
exogenous antigens by melanoma-like nonprofessional APC
not only requires the expression of the various genes con-
trolled by the transactivator CIITA (namely, MHC class 11
genes, HLA-DM, and the Ii gene), but also depends on the
induction, by IFN-y, of other factors required for process-
ing ofprotein antigens. Whether these factors result in sub-
tle modifications in postendocytic trafficking steps, in the
availability or activity o£ specific proteases, or in other yet
unknown protein-protein interactions is now open for study
(Fig. 5). The demonstration that antigen-processing-defec-
tive cells ofany desired HLA-DR haplotype can be obtained
simply by CIITA transfection of nonprofessional APC
should now greatly facilitate the search for these factors .
Whatever the exact mechanism, this observation could
have practical implications in the field of cancer immuno-
therapy: transfection of the CIITA gene is indeed consid-
ered a way to convert tumor cells into efficient MHC class
11-positive APC. This way might not be sufficient for in-
duction of T cells that are specific for tumor antigens. Fur-
thermore, the identification of an additional requirement
for antigen processing by nonprofessional APC that express
MHC class II molecules, and its control by IFN-y, appears
important in terms of the physiological regulation of im-
mune responses. Indeed, the inability of nonprofessional
APC throughout the body to adequately process exoge-
nous antigens would limit the risk of inducing immune re-
sponses to numerous environmental antigens. As a signifi-
cant example, enterocytes have been shown to constitutively
express MHC class II molecules of abnormal conformation
and to be defective in T cell activation (21) . In contrast, in
the context oflocal inflammation, cytokines released in the
microenvironment would simultaneously activate MHC class
II expression and antigen-processing mechanisms, thus re-
sulting in effective antigen presentation.
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